Role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in tumour progression and sensitivity to doxifluridine in gastric cancer patients

European Journal of Cancer

Volumn 38, Issue 18, 2002, Pages 2375-2381

  Terashima, M ^a   Fujiwara, H ^b   Takagane, A ^b   Abe, K ^b   Araya, M ^b   Irinoda, T ^b   Yonezawa, H ^b   Nakaya, T ^b   Oyama, K ^b   Takahashi, M ^b   Saito, K ^b  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^b IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

Dihydropyrimidine dehydrogenase; Doxyfluridine; Drug sensitivity testing; Gastric cancer; Thymidine phosphorylase

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; DOXIFLURIDINE; THYMIDINE PHOSPHORYLASE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; STOMACH CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; DIHYDROURACIL DEHYDROGENASE (NADP); DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOXURIDINE; HUMANS; MALE; MIDDLE AGED; OXIDOREDUCTASES; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; THYMIDINE PHOSPHORYLASE;

EID: 0036892789     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00380-5     Document Type: Article

References (30)

1. Miyadera K., Sumizawa T., Haraguchi Met al. Role of thymidine phosphorylase activity in the angiogenic effect of platelet derived endothelial cell growth factor/thymidine phosphorylase. Cancer Res. 55:1995;1687-1690.
2. Kakeji Y., Maehara Y., Shibahara K.et al. Heterogeneity and clinical role of thymidine phosphorylase activity in gastric cancer. Oncol. Rep. 6:1999;1213-1216.
3. Maeda K., Chung Y.S., Ogawa Y.et al. Thymidine phosphorylase/platelet-derived endothelial cell growth factor expression associated with hepatic metastasis in gastric carcinoma. Br. J. Cancer. 73:1996;884-888.
4. Tanigawa N., Amaya H., Matsumura M.et al. Tumor angiogenesis and expression of thymidine phosphorylase/platelet derived endothelial cell growth factor in human gastric carcinoma. Cancer Lett. 108:1996;281-290.
5. Yonenaga F., Takasaki T., Ohi Y.et al. The expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor is correlated to angiogenesis in breast cancer. Pathol. Int. 48:1998;850-856.
6. Takebayashi Y., Akiyama S., Akiba S.et al. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J. Ntl. Cancer Inst. 88:1996;1110-1117.
7. Cook A.F., Holman M.J., Kramer M.J., Trown P.W. Fluorinated pyrimidine nucleosides. 3. Synthesis and antitumor activity of a series of 5′-deoxy-5-fluoropyrimidine nucleosides. J. Med. Chem. 22:1979;1330-1335.
8. Schuller J., Cassidy J., Dumont E.et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother. Pharmacol. 45:2000;291-297.
9. Ishikawa T., Sekiguchi F., Fukase Y., Sawada N., Ishitsuka H. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res. 58:1998;685-690.
10. Koizumi W., Saigenji K., Nakamaru N., Okayasu I., Kurihara M. Prediction of response to 5′-deoxy-5-fluorouridine (5′-DFUR) in patients with inoperable advanced gastric cancer by immunostaining of thymidine phosphorylase/platelet-derived endothelial cell growth factor. Oncology. 56:1999;215-222.
11. Heggie G.D., Sommadossi J.P., Cross D.S., Huster W.J., Diasio R.B. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 47:1987;2203-2206.
12. Harris B.E., Song R., Soong S.J., Diasio R.B. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res. 50:1990;197-201.
13. Takimoto C.H., Lu Z.H., Zhang R.et al. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin. Cancer Res. 2:1996;477-481.
14. Etienne M.C., Cheradame S., Fischel J.L.et al. Response to fluorouracil therapy in cancer patients. the role of tumoral dihydropyrimidine dehydrogenase activity J. Clin. Oncol. 13:1995;1663-1670.
15. Beck A., Etienne M.C., Cheradame S.et al. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur. J. Cancer. 30A:1994;1517-1522.
16. Terashima M, Irinoda T, Fujiwara H, et al. Role of thymidylate synthase and dihydropyrimidine dehydrogenase on tumor progression and sensitivity to 5-fluorouracil in human gastric cancer. Anticancer Res 2002, 22, 761-768.
17. Association of Japanese Gastric Carcinoma. Japanese classification of gastric carcinoma [2nd English edition]. Gastric Cancer 1998, 1, 10-24.
18. Nishida M., Hino A., Mori K., Matsumoto T., Yoshikubo T., Ishitsuka H. Preparation of anti-human thymidine phosphorylase monoclonal antibodies useful for detecting the enzyme levels in tumor tissues. Biol. Pharm. Bullt. 19:1996;1407-1411.
19. Mori K., Hasegawa M., Nishida M.et al. Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues. Int. J. Oncol. 17:2000;33-38.
20. Kawamura H., Ikeda K., Takiyama I., Terashima M. The usefulness of the ATP assay with serum-free culture for chemosensitivity testing of gastrointestinal cancer. Eur. J. Cancer. 33:1997;960-966.
21. Toi M., Hoshina S., Taniguchi T., Yamamoto Y., Ishitsuka H., Tominaga T. Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast cancer. Int. J. Cancer. 64:1995;79-82.
22. Griffiths L., Dachs G.U., Bicknell R., Harris A.L., Stratford I.J. The influence of oxygen tension and pH on the expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast tumor cells grown in vitro and in vivo. Cancer Res. 57:1997;570-572.
23. Eda H., Fujimoto K., Watanabe S.et al. Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine. Cancer Chemother. Pharmacol. 32:1993;333-338.
24. Endo M., Shinbori N., Fukase Y.et al. Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5′-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models. Int. J. Cancer. 83:1999;127-134.
25. Ogawa K., Konno S., Takebayashi Y.et al. Clinicopathological and prognostic significance of thymidine phosphorylase expression in gastric carcinoma. Anticancer Res. 19:1999;4363-4367.
26. Ishikawa Y., Kubota T., Otani Y.et al. Thymidylate synthetase and dihydropyrimidine dehydrogenase levels in gastric cancer. Anticancer Res. 19:1999;5635-5640.
27. Johnston S.J., Ridge S.A., Cassidy J., McLeod H.L. Regulation dihydropyrimidine dehydrogenase in colorectal cancer. Clin. Cancer Res. 5:1999;2566-2570.
28. Kanyama H., Tomita N., Yamano T.et al. Enhancement of the anti-tumor effect of 5′-deoxy-5-fluorouridine by transfection of thymidine phosphorylase gene into human colon cancer cells. Jap. J. Cancer Res. 90:1999;454-459.
29. Patterson A.V., Zhang H., Moghaddam A.et al. Increased sensitivity to the prodrug 5′-deoxy-5-fluorouridine and modulation of 5-fluoro-2′-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase. Br. J. Cancer. 72; 1995;669-675.
30. Collie-Duguid E.S.R., Johnston S., Boyce L. Thymidine phosphorylase and dihydropyrimidine dehydrogenase protein expression in colorectal cancer. Int. J. Cancer. 94:2001;297-301.